e-Article
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
Document Type
Article
Author
Hizal, M.; Bilgin, B.; Yaman, Ş.; Paksoy, N.; Aydıner, A.; Atcı, M.M.; Sakin, A.; Kahraman, S.; Yalçın, B.; Şendur, M.A.N.; Kılıçkap, S.; Güven, D.C.; Keskinkılıç, M.; Öztop, İ.; Ayhan, M.; Eren, Ö.; Mustafayev, F.N.A.; Özgün, M.A.; Bayram, E.; Ertürk, İ.; Özcan, E.; Korkmaz, M.; Akagündüz, B.; Erdem, D.; Telli, T.A.; Aksoy, A.; Üskent, N.; Baytemür, N.K.; Gülmez, A.; Aydın, D.; Şakalar, T.; Arak, H.; Tatlı, A.M.; Ergün, Y.; Ak, N.; Ünal, Ç.; Algın, E.; Yumuk, P.F.
Source
In: Journal of Cancer Research and Clinical Oncology . (Journal of Cancer Research and Clinical Oncology, July 2023, 149(8):4141-4148)
Subject
Language
English
ISSN
14321335
01715216
01715216